Antoni Chan MD (Prof) synovialjoints
5 days 10 hours ago
Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks.
SUA <300 μmol/L at Week 36:
63.8% vs 40.7% (p<0.0001)
A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile
Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS
Md Yuzaiful Md Yusof Yuz6Yusof
5 days 10 hours ago
#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1
Dr. John Cush RheumNow
1 week ago
New Insights in Gout Clinical Management
https://t.co/Eo63NUhaY2 https://t.co/oHZG1c1LhL
Bella Mehta bella_mehta
1 week ago
Weight management should be discussed!!
Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist.
Best evidence in OA and Gout.
#EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu
Aurelie Najm AurelieRheumo
1 week 1 day ago
ULT de-escalation in Gout: shall we do it?
Short answer: No
RCT 309 pts 24 mo
Primary outcome remission last 6 mo
79.2% ULT continuation vs 62.9% discontinuation p=0.002
Flare incidence 12% vs 32%
More NSAID/colchicine use after stopping ULT
Stopping ULT = urate rises quickly & https://t.co/bYKr5axu46
EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where gout was high on the agenda. Current guidelines recommend lifelong urate-lowering therapy (ULT) in a treat-to-target (T2T) strategy to maintain remission, although there is some scope for discussing tapering or discontinuation if remission is achieved.
